Study To Assess Efficacy Safety And Pharmacokinetics Of

Recruiting

99 years or below

All

Phase 2

3 participants needed

1 Location

Brief description of study

The main purpose of this study is to evaluate the efficacy and safety of the investigational drug iptacopan (LNP023) in people with primary ITP or primary CAD. You will be in the study about 6 months with the opportunity to extend the total duration to about 31 months if you respond well to the treatment.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: autoimmune, hematologic disorders
Age: 99 years or below
Gender: All

Updated on 04 Aug 2024. Study ID: 850646

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Study To Assess Efficacy Safety And Pharmacokinetics Of Iptacopan (LNP023) In Participants With Autoimmune Benign Hematological Disorders

Brief description of study

Eligibility of study

Find a site

Interested in the study